(Image source: mainjustice) The FDA has approved Pfizer Inc.’s (NYSE:PFE) new drug treatment for moderate-to-several hot flashes and osteoporosis in post-menopausal for women. The drug is called Duavee, which was created in association with Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Duavee is made from a combination of bazedoxifene and estrogens. According to the press release, “Results from one trial demonstrated that DUAVEE significantly reduced the number of moderate-to-severe hot flashes by 74% at 12 weeks, as compared with placebo (47%).”